Turn Therapeutics Inc stock analysis
Want to see TTRX full AI Analyst Report?
Turn Therapeutics Inc (TTRX) Stock Price & Analysis
TTRX Stock Chart & Stats
- Day’s Range
- $8.09 - $9.11
- 52-Week Range
- $2.57 - $16.45
- Previous Close
- $8.55
- Volume
- N/A
- Average Volume (3M)
- 98.74K
- Market Cap
- $261.40M
- Enterprise Value
- $429.54M
- Total Cash (Recent Filing)
- $10.36M
- Total Debt (Recent Filing)
- $490.55K
- Price to Earnings (P/E)
- ―
- Beta
- 0.55
- Next Earnings
- Apr 06, 2027 (Est.)
- EPS Estimate
- -0.12
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
GX-03 Platform Differentiation
The proprietary PermaFusion platform and GX-03’s reported patient experience provide a potentially differentiated foundation in topical inflammatory and infectious disease therapies. If these characteristics remain supported through development, they could strengthen product positioning and expand applications across skin, nails, and mucous membranes.
Clinical Development Progress
Completion of the initial Phase 2 stage and progression into a larger optimized cohort demonstrate that GX-03 has advanced beyond early development. The defined efficacy endpoints and planned milestones create a clearer path for generating clinical evidence and potentially broadening the company’s dermatology pipeline.
Scientific Leadership
Adding an experienced physician-scientist with backgrounds in immunology, infectious disease, and public health may improve the quality of scientific and clinical decision-making. His role across multiple GX-03 indications could help coordinate the platform’s development strategy as the pipeline expands.
Bears Say
Pre-revenue Operating Model
Essentially no revenue combined with materially wider losses indicates that commercial traction has not yet emerged, while operating costs remain substantial. This leaves the company reliant on future development success before it can establish a self-sustaining earnings base or demonstrate durable operating leverage.
Persistent Cash Consumption
Ongoing and worsening negative cash flow means the business is consuming capital rather than funding its operations internally. Continued cash use can limit the resources available for clinical development and make financial stability increasingly dependent on successfully securing additional capital.
Dependence On External Funding
Reliance on external funding is a structural weakness while the company remains pre-revenue and loss-making. Until commercial traction develops, financing availability will remain important to sustaining research and operations, which can constrain strategic flexibility and increase execution pressure.
Turn Therapeutics Inc News
Turn Therapeutics announces publication of peer-reviewed research on GX-03
Turn Therapeutics (TTRX) announced the publication of new peer-reviewed research providing in-vivo evidence that its lead investigational therapy, GX-03, selectively reduces several important inflammatory signals associated with inflammatory skin disease.
TTRX FAQ
What was Turn Therapeutics Inc’s price range in the past 12 months?
What is Turn Therapeutics Inc’s market cap?
When is Turn Therapeutics Inc’s upcoming earnings report date?
How were Turn Therapeutics Inc’s earnings last quarter?
Is Turn Therapeutics Inc overvalued?
Does Turn Therapeutics Inc pay dividends?
What is Turn Therapeutics Inc’s EPS estimate?
How many shares outstanding does Turn Therapeutics Inc have?
What happened to Turn Therapeutics Inc’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Turn Therapeutics Inc?
What is the TipRanks Smart Score and how is it calculated?
Turn Therapeutics Inc Stock Smart Score
Company Description
Turn Therapeutics Inc
Turn Therapeutics Inc., officially known as Global Health Solutions, Inc., is a pharmaceutical enterprise dedicated to developing treatments for conditions affecting the skin, nails, and eyes. The company utilizes a proprietary drug delivery system engineered to effectively permeate skin and nail tissues. This advanced technology is integrated into their solutions for both acute and chronic wound care, specifically designed to help combat antibiotic resistance. Consequently, these products empower healthcare institutions to effectively manage a broad spectrum of dermatological challenges, encompassing everything from sudden injuries and persistent wounds to general skin ailments and specific dermatoses. Global Health Solutions, Inc. was established in 2015 and maintains its headquarters in Westlake Village, California.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Bradley E. Burnam
- Employees
- 2
- Website
- www.turntherapeutics.com
- Address
- 250 N Westlake Blvd, Westlake Village, CA, 91362, US
Turn Therapeutics Inc (TTRX) Earnings & Revenues
TTRX Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 4 | 12 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 2 | 0 | 10 |









